Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Hang Su et al.|The Lancet Haematology|2019Cited by 248
Genomic and Transcriptomic Characterization of Natural Killer T Cell LymphomaJie Xiong, Weili Zhao, Bowen Cui et al.|Cancer Cell|2020Cited by 234
Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivoZhenzhen Chen, Wenbin Qian|Journal of Experimental & Clinical Cancer Research|2018Cited by 86
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cellsWei He, Wenbin Qian|International Journal of Oncology|2016Cited by 42
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Wei Zhang et al.|EBioMedicine|2020Cited by 41